VIDEO: Roman Hovorka, PhD, Talks About the Cost and Coverage Issues Associated with Continuous Glucose Monitoring
Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.
Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.
According to Hovorka, there are more issues in the United Kingdom compared to the United States at this time, although the costs of of continuous glucose monitoring prohibit widespread use in both countries.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025
- Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
September 17th 2025
- Assessing the Rising Prevalence of Early-Onset Type 2 Diabetes in the US
September 16th 2025